All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2022; the latest 2022-12-05.
From the record
Zymeworks Inc.'s filings since 2022 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2022-12-05) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+22.2% a year over 6 filed years; profitable in 1 of 6.
From the record
Zymeworks Inc.'s 6 filed years say what it did: revenue went from $39 million in fiscal 2020 to $106 million in fiscal 2025, up 22.2% a year; it rose in 3 of 5 years; the deepest fall was 82% from fiscal 2022 to fiscal 2023; net income was positive in 1 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 7.4/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Zymeworks Inc.'s shareholder treatment is put at 7.4 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 26% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -30%: lost 30¢ per shareholder dollar. Leverage 23%: owes 23¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Zymeworks Inc. lost about 30 cents for every dollar of shareholders' money. Leverage: it owed about 23 cents per dollar of assets, and net share issuance: its share count shrank 0.6% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 45% of 315 in its family; net margin -76.6%.
From the record
Zymeworks Inc.'s standing among 315 graded names in its industry family: revenue of $106 million in fiscal 2025 ranks in the top 35% by size; a net margin of -76.6% ranks in the top 44%; revenue growth of -36.4% a year over the last 3 filed years ranks in the bottom 13% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 13% of 315 in its family for leadership; chief executive since 2022.
From the record
Zymeworks Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Galbraith, Kenneth (Chair & CEO, as filed), filing under that title since the record of its people begins (2022-10-17), so the years before are not on the record and this part is not read; the 17 officers and directors filing in the last fifteen months have been on the record a median of 2.2 years (bottom 8%); 14 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (bottom 19%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 47% of 273 in its family for room to expand.
From the record
Zymeworks Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $41 million against no long-term debt tagged leaves 11.9% of its assets as net cash, bottom 29% of its family; cash from operations less capital spending is -32.6% of revenue (top 42%); research spending of 129.3% of revenue (top 47%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 33% of 306 in its family for growth drivers.
From the record
Zymeworks Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -36.4% a year over the last three filed years against 22.2% over all 6, slowing (bottom 10% of its family); the newest year grew 38.9% (top 30%); research spending grew -13.1% a year (bottom 26%); capital spending grew -42.8% a year (bottom 27%) (its annual reports). Zymeworks Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 47% of 233 in its family for expectations against reality.
From the record
Zymeworks Inc.'s newest year against its own record: revenue of $106 million in fiscal 2025 came in 222.7% above the $33 million its prior three years' pace pointed to (top 11% of its family); net income of $81 million against a prior three-year average of $39 million (bottom 14%); a net margin of -76.6% against -95.6% before (top 45%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made